StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Humalog (insulin lispro) by Quarter

Humalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

QuarterlyAnnual

Eli Lilly Humalog (insulin lispro): $620M in Q4 2024, up 69.1% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
620
Period ended Dec 31, 2024
Change on a year earlier
+69.1%
367 in Q4 2023
History
32 quarters
Since Q1 2017
Sources
28
Documents cited below

Where the Q4 2024 figure comes from

“|| Humalog (b) | 619.9 | 366.6 | 69% | 2,324.8 | 1,663.3 | 40%”

Source: Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗

Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedHumalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
Q4 2024Dec 31, 2024620+69.1%Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗
Q3 2024Sep 30, 2024535+35.2%Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024632+43.4%Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024539+16.9%Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023367-33.1%Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 2023395-11.5%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023440-1.5%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023461-25.4%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022548-8.9%Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022447-28.7%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 2022447-26.4%Form 10-Q (filed 2023-08-08) ↗
Q1 2022Mar 31, 2022618+0.2%Form 10-Q (filed 2023-04-27) ↗
Q4 2021Dec 31, 2021602-16.2%Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 2021627-4.6%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 2021608+9.5%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021617-11.3%Form 10-Q (filed 2022-04-29) ↗

Breakdown

What makes up humalog (insulin lispro)

Cite this data

StockData. (2026). Eli Lilly Humalog (insulin lispro) ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-humalog-ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.